Clinical Trial

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-06-16; most recent amendment 2024-03-13.
Trial Details
NCT Number NCT05425576
Lead Sponsor Oncotelic Inc.
Conditions Malignant Pleural Mesothelioma
Enrollment 63 participants
Start Date 2025-06
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2024-03-15